Adagene Inc (ADAG)

Currency in USD
1.905
-0.095(-4.77%)
Real-time Data·
ADAG Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
ADAG is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
1.9052.040
52 wk Range
1.3253.581
Key Statistics
Prev. Close
1.99
Open
2
Day's Range
1.905-2.04
52 wk Range
1.325-3.581
Volume
10.81K
Average Volume (3m)
68.91K
1-Year Change
-21.03%
Book Value / Share
1.14
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
ADAG Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
10.857
Upside
+469.90%
Members' Sentiments
Bearish
Bullish
ProTips
Analysts anticipate sales growth in the current year

Adagene Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell

Adagene Inc Company Profile

Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers in the People’s Republic of China. Its lead product candidate is the ADG126, a masked fully-human anti-CTLA-4 mAb which is in phase 1b/2 clinical development for the treatment of cancer. The company also develops ADG116, a fully human anti-CTLA-4 antibody generated using NEObody technology, which is in phase 1b/2 clinical trials to treat advanced/metastatic solid tumors; ADG206, which is in phase 1 clinical development to treat advanced metastatic solid tumors; ADG104, anti-PD-L1 monoclonal antibody which is in phase 2 clinical development; and ADG125, a novel anti-CSF-1R mAb which is in Phase 2 clinical development. In addition, it is developing ADG138, a HER2xCD3 POWERbody which is in pre clinical trial to treat low expressing tumors, as well as resistant/refractory tumors; ADG152, a CD20xCD3 POWERbody which is in preclincal trial to treat off-tumor toxicities; ADG153, a masked anti-CD47 IgG1 SAFEbody, wihx is in preclinical trial for the treatment of hematologic and solid tumor; and CD28 T-cell engagers, an anti-CD28 bispecific POWERbody TCEs to treat solid tumors. The company was incorporated in 2011 and is headquartered in Suzhou, China.

Compare ADAG to Peers and Sector

Metrics to compare
ADAG
Peers
Sector
Relationship
P/E Ratio
−2.8x−3.3x−0.5x
PEG Ratio
0.04−0.010.00
Price/Book
1.9x2.4x2.6x
Price / LTM Sales
908.4x9.8x3.2x
Upside (Analyst Target)
302.0%277.1%41.6%
Fair Value Upside
Unlock6.0%6.0%Unlock

Analyst Ratings

2 Buy
2 Hold
0 Sell
Ratings:
4 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 10.857
(+469.90% Upside)

Earnings

Latest Release
May 28, 2025
EPS / Forecast
-- / --
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

ADAG Income Statement

People Also Watch

14.35
DXC
+0.34%
7.170
CAPR
+1.56%
103.19
CRUS
+1.99%
5.7100
ATHE
-12.82%
254.83
BIO
-3.54%

FAQ

What Stock Exchange Does Adagene Trade On?

Adagene is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Adagene?

The stock symbol for Adagene is "ADAG."

What Is the Adagene Market Cap?

As of today, Adagene market cap is 92.33M.

What Is Adagene's Earnings Per Share (TTM)?

The Adagene EPS (TTM) is -0.74.

When Is the Next Adagene Earnings Date?

Adagene will release its next earnings report on 26 Aug 2025.

From a Technical Analysis Perspective, Is ADAG a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Buy.

How Many Times Has Adagene Stock Split?

Adagene has split 0 times.

How Many Employees Does Adagene Have?

Adagene has 138 employees.

What is the current trading status of Adagene (ADAG)?

As of 28 Jul 2025, Adagene (ADAG) is trading at a price of 1.91, with a previous close of 1.99. The stock has fluctuated within a day range of 1.91 to 2.04, while its 52-week range spans from 1.33 to 3.58.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.